Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06628921

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

Sponsor: University of Florence

View on ClinicalTrials.gov

Summary

A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

50

Start Date

2024-10-30

Completion Date

2026-10-30

Last Updated

2026-01-21

Healthy Volunteers

No

Conditions

Interventions

DRUG

Eptinezumab 100 or 300 mg ev

Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.

Locations (1)

Campus Biomedico

Roma, Italy